Page last updated: 2024-10-15

krm 1657

Description

KRM 1657: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135433376
CHEMBL ID4647002
CHEBI ID34806
SCHEMBL ID1649985
MeSH IDM0188431

Synonyms (10)

Synonym
133633-12-2
[tetrahydroxy-methoxy-heptamethyl-trioxo-(4-propylpiperazin-1-yl)[?]yl] acetate
krm 1657
3'-hydroxy-5'-(4-propylpiperazinyl)benzoxazinorifamycin
rifamycin viii, 1',4-didehydro-1-deoxy-1,4-dihydro-3'-hydroxy-1-oxo-5'-(4-propyl-1-piperazinyl)-
krm-1657
SCHEMBL1649985
CHEBI:34806
Q27116278
CHEMBL4647002
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID1653518Anti-leprotic activity against rifampicin-susceptible Mycobacterium leprae subcultures at 4 weeks assessed as ATP level per 10'7 cells at 0.4 mg/L measured by bioluminescence assay (Rvb = 425 +/- 64 pg)2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID1653396Anti-leprotic activity against rifampicin-susceptible Mycobacterium leprae subcultures at 4 weeks assessed as ATP level per 10'7 cells at 0.1 mg/L measured by bioluminescence assay (Rvb = 425 +/- 64 pg)2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID1653390Anti-leprotic activity against rifampicin-susceptible Mycobacterium leprae subcultures at 4 weeks assessed as ATP level per 10'7 cells at 0.2 mg/L measured by bioluminescence assay (Rvb = 425 +/- 64 pg)2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID1653521Anti-leprotic activity against rifampicin-susceptible Mycobacterium leprae subcultures at 4 weeks assessed as [3H]thymidine uptake per 5 times 10'7 cells at 0.1 mg/L incubated for 24 hrs (Rvb = 1.41 +/- 0.20 pmol)2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID1653509Anti-leprotic activity against rifampicin-susceptible Mycobacterium leprae primary cultures at 4 weeks assessed as ATP level per 10'7 cells at 0.1 mg/L measured by bioluminescence assay (Rvb = 332 +/- 46 pg)2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID1653512Anti-leprotic activity against rifampicin-susceptible Mycobacterium leprae primary cultures at 4 weeks assessed as ATP level per 10'7 cells at 0.4 mg/L measured by bioluminescence assay (Rvb = 332 +/- 46 pg)2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID1653522Anti-leprotic activity against rifampicin-susceptible Mycobacterium leprae subcultures at 4 weeks assessed as [3H]thymidine uptake per 5 times 10'7 cells at 0.2 mg/L incubated for 24 hrs (Rvb = 1.41 +/- 0.20 pmol)2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID1653511Anti-leprotic activity against rifampicin-susceptible Mycobacterium leprae primary cultures at 4 weeks assessed as ATP level per 10'7 cells at 0.3 mg/L measured by bioluminescence assay (Rvb = 332 +/- 46 pg)2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID1653510Anti-leprotic activity against rifampicin-susceptible Mycobacterium leprae primary cultures at 4 weeks assessed as ATP level per 10'7 cells at 0.2 mg/L measured by bioluminescence assay (Rvb = 332 +/- 46 pg)2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID1653515Anti-leprotic activity against rifampicin-susceptible Mycobacterium leprae primary cultures at 4 weeks assessed as [3H]thymidine uptake per 5 times 10'7 cells at 0.1 mg/L incubated for 24 hrs (Rvb = 1.05 +/- 0.16 pmol)2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID1653508Anti-leprotic activity against rifampicin-susceptible Mycobacterium leprae primary cultures at 4 weeks assessed as [3H]thymidine uptake per 5 times 10'7 cells at 0.3 mg/L incubated for 24 hrs (Rvb = 1.05 +/- 0.16 pmol)2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID1653517Anti-leprotic activity against rifampicin-susceptible Mycobacterium leprae primary cultures at 4 weeks assessed as [3H]thymidine uptake per 5 times 10'7 cells at 0.4 mg/L incubated for 24 hrs (Rvb = 1.05 +/- 0.16 pmol)2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID1653392Anti-leprotic activity against rifampicin-susceptible Mycobacterium leprae subcultures at 4 weeks assessed as ATP level per 10'7 cells at 0.3 mg/L measured by bioluminescence assay (Rvb = 425 +/- 64 pg)2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID1653523Anti-leprotic activity against rifampicin-susceptible Mycobacterium leprae subcultures at 4 weeks assessed as [3H]thymidine uptake per 5 times 10'7 cells at 0.3 mg/L incubated for 24 hrs (Rvb = 1.41 +/- 0.20 pmol)2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID1653516Anti-leprotic activity against rifampicin-susceptible Mycobacterium leprae primary cultures at 4 weeks assessed as [3H]thymidine uptake per 5 times 10'7 cells at 0.2 mg/L incubated for 24 hrs (Rvb = 1.05 +/- 0.16 pmol)2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID1653524Anti-leprotic activity against rifampicin-susceptible Mycobacterium leprae subcultures at 4 weeks assessed as [3H]thymidine uptake per 5 times 10'7 cells at 0.4 mg/L incubated for 24 hrs (Rvb = 1.41 +/- 0.20 pmol)2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (60.00)18.2507
2000's1 (20.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]